Asuragen Overview

  • Founded
  • 2005

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 144

Employees
  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $321M

  • Investors
  • 1

Asuragen General Information

Description

Developer of molecular diagnostic products designed to optimize patient management in oncology and genetic diseases. The company presents a wide range of kits and assays for genetic sequencing as well as cancer monitoring, enabling the medical community to enhance treatment outcomes through accurate data.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Other Healthcare Technology Systems
Parent Company
Primary Office
  • 2150 Woodward Street
  • Suite 100
  • Austin, TX 78744
  • United States
+1 (512) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Asuragen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 06-Apr-2021 $321M 000.00 00000 Completed Generating Revenue
7. Debt - PPP 27-Apr-2020 00.000 000.00 Completed Generating Revenue
6. Later Stage VC (Series C) 20-Mar-2013 00.00 000.00 00000 Completed Generating Revenue
5. Grant 30-Mar-2012 00.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series C) 11-Aug-2011 000 000.00 000.00 Completed Generating Revenue
3. Grant 08-Oct-2008 00.00 000.00 Completed Startup
2. Early Stage VC (Series B) 10-Dec-2007 $18.5M $67.4M 000.00 Completed Startup
1. Early Stage VC (Series A) 01-Jun-2006 $48.9M $48.9M 000.00 Completed Startup
To view Asuragen’s complete valuation and funding history, request access »

Asuragen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.0 00.0 00 00.0 00.000
Series A 48,895,000 $0.001000 $1 $1 1x $1 55.48%
To view Asuragen’s complete cap table history, request access »

Asuragen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of molecular diagnostic products designed to optimize patient management in oncology and genetic diseases. The
Diagnostic Equipment
Austin, TX
144 As of 2021
000.00
0000 0000-00-00
000000&0 000.00

000000

sum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolor
0000000000 000000000
Cambridge, MA
0000 As of 0000
00000
0.000 0000-00-00
00000000000

000000

inim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000000000 00000000 (0000000000)
San Diego, CA
000 As of 0000
000.00
0000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Asuragen Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Foundation Medicine Formerly VC-backed Cambridge, MA 0000 00000 00000000000
000000000000000 Formerly VC-backed San Diego, CA 000 000.00 000000&0 000.00
0000000 0000000000 Formerly VC-backed Menlo Park, CA 000 00000 000000000 00000
000000000 Formerly VC-backed Rostock, Germany 000 00000 000000000 00000
000000 000000000 Formerly PE-Backed Codolet, France 000 000000&0
You’re viewing 5 of 16 competitors. Get the full list »

Asuragen Patents

Asuragen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210189384-A1 Methods and compositions for amplicon concatenation Pending 26-Nov-2019 00000000000
US-11236384-B2 Methods of rna amplification Active 19-Jan-2017 000000000
US-20220177949-A1 Methods of rna amplification Pending 19-Jan-2017 000000000
US-20200140923-A1 Methods of rna amplification Active 19-Jan-2017 000000000
CA-3002088-A1 Methods for nucleic acid size detection of repeat sequences Pending 03-Nov-2015 C12Q1/6851
To view Asuragen’s complete patent history, request access »

Asuragen Executive Team (18)

Name Title Board Seat Contact Info
Bernard Andruss Ph.D Chief Operating Officer
Gary Latham Ph.D Chief Scientific Officer
Debra Thompson Vice President, Human Resources
You’re viewing 3 of 18 executive team members. Get the full list »

Asuragen Board Members (13)

Name Representing Role Since
Christopher Earl Ph.D Asuragen Board Member 000 0000
David Sargent Self Board Member 000 0000
Deval Lashkari Ph.D Telegraph Hill Partners Board Member 000 0000
Matthew Crawford PTV Healthcare Capital Board Member 000 0000
You’re viewing 4 of 13 board members. Get the full list »

Asuragen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Asuragen Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Growth Capital Fund Venture Capital Minority 000 0000 000000 0
Merck Global Health Innovation Fund Corporate Venture Capital Minority 000 0000 000000 0
PTV Healthcare Capital Venture Capital Minority 000 0000 000000 0
Southwest Middle Market M&A Merchant Banking Firm Minority 000 0000 000000 0
State Of Texas Real Estate Fund Real Estate 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Asuragen Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 01-Jan-2009 00000 0000 000 Biotechnology 0000000 0
Mirna Therapeutics 04-Apr-2008 Seed Round 000 Biotechnology 0000000 0
To view Asuragen’s complete investments history, request access »

Asuragen Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 000000000000 01-Jan-2009 00000 00000 00 000 Completed
  • 00000000
Mirna Therapeutics 04-Apr-2008 Seed Round 000 Completed
To view Asuragen’s complete exits history, request access »